ReviewAging and disease2023
Exploring the Intricate Nexus of Sarcopenia and Cognitive Impairment.
Review in Aging and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- A causal relationship between sarcopenia and cognitive impairment: A Mendelian randomization study.PloS one · 2024Pooled it
- Impact of a nurse-led multidomain intervention on intrinsic capacity among community-dwelling older adults in China: a cluster randomized trial.BMC public health · 2025Trial
- Association between geriatric malnutrition and the risk of dementia: a retrospective cross-sectional cohort study in Uganda.BMC geriatrics · 2026Article
- Effects of Sarcopenia and Frailty on Cognitive Function, Brain Volume, and Dementia Risk: A Prospective Cohort Study Based on UK Biobank.Dementia and neurocognitive disorders · 2026Article
- Nutritional intervention targeting muscle-brain axis in dementia continuum: from mechanisms to practice.Frontiers in nutrition · 2026Review
- Muscle Ultrasound Parameters and Cognitive Function in H‑type Hypertension: A Cross-Sectional Study.Clinical interventions in aging · 2026Article
- Synergistic effects of multicomponent exercise and rTMS on sarcopenia and mild cognitive impairment in older people: a protocol for a randomized controlled trial.BMC geriatrics · 2025Article
- Acupuncture combined with exercise therapy for Sarcopenia in the elderly: A multicenter randomized controlled study protocol.MethodsX · 2025Article
- Bidirectional association between grip strength and cognitive function in Chinese older adults: a nationwide cohort study.BMC public health · 2025Article
- The Link Between Oxysterols and Gut Microbiota in the Co-Dysfunction of Cognition and Muscle.Nutrients · 2025Article
- Interaction and overall effects of underweight, low muscle mass, malnutrition, and inflammation on early-onset mild cognitive impairment in type 2 diabetes.Frontiers in aging neuroscience · 2025Article
- Exploring the role of Transcranial magnetic stimulation in cognitive impairment and sarcopenia: a narrative review.Frontiers in human neuroscience · 2025Review
- Advancements in Single-Cell RNA Sequencing Research for Neurological Diseases.Molecular neurobiology · 2024Review
- Cognition as mediator of pulmonary function and risk of sarcopenia among older adults.BMC public health · 2024Article
- Multicomponent exercise improved cognitive flexibility and muscular fitness in community-dwelling older adults.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia, a group of skeletal muscle diseases with high prevalence in older adults, usually manifests as loss of muscle mass and strength, and/or physical performance decline. Cognitive impairment, defined as impaired function in one or more cognitive domains such as memory, language, computation, comprehension, executive, and visuospatial skills, affects the quality of life and social functioning of patients. Both sarcopenia and cognitive impairment are common geriatric syndromes, and the two disorders interact and influence each other. Declining muscle function accelerates cognitive impairment, and cognitive impairment in turn affects muscle strength. Potential common pathological mechanisms between the two include chronic inflammation, mitochondrial dysfunction and oxidative stress, and gut microbiota disorder. Additionally, neuroendocrine connections including testosterone, insulin, and growth factors have important effects on muscle and brain function. Recently, the development of applied metabolomics technologies has shown significant potential in uncovering shared biochemical pathways and exploring potential biomarkers. Exercise, nutritional, and cognitive interventions are significant as nonpharmacologic approaches in the treatment of sarcopenia and cognitive impairment. However, the specific mechanism of interaction between two diseases, biomarkers and effective therapeutic medications still has knowledge gaps that need to be further explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.